Case Report

Eosinophilic Granulomatosis with Polyangiitis Presenting as Acute Polyneuropathy Mimicking Guillain-Barre Syndrome

Carlos R. Camara-Lemarroy, Adrian Infante-Valenzuela, Hector J. Villareal-Montemayor, Carlos A. Soto-Rincon, Javier A. Davila-Olalde, and Hector J. Villareal-Velazquez

1Servicio de Neurologia, Hospital Universitario “Dr. José E. González” y Facultad de Medicina, Universidad Autónoma de Nuevo León, Madero y Gonzalitos, S/N, 64460 Monterrey, NL, Mexico
2Departamento de Medicina Interna, Hospital Universitario “Dr. José E. González” y Facultad de Medicina, Universidad Autónoma de Nuevo León, Madero y Gonzalitos, S/N, 64460 Monterrey, NL, Mexico

Correspondence should be addressed to Carlos R. Camara-Lemarroy; crcamara83@hotmail.com

Received 26 May 2015; Revised 13 June 2015; Accepted 15 June 2015

Academic Editor: Peter Berlit

Copyright © 2015 Carlos R. Camara-Lemarroy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCAs) which commonly affects the peripheral nervous system. A 38-year-old female with a history of asthma presented with a 2-week history of bilateral lower extremity paresthesias that progressed to symmetric ascending paralysis. Nerve conduction studies could not rule out Guillain-Barre syndrome (GBS) and plasmapheresis was considered. Her bloodwork revealed marked eosinophilia (>50%), she had purpuric lesions in her legs, and a head magnetic resonance image showed evidence of pansinusitis. Coupled with a history of asthma we suspected EGPA-associated neuropathy and started steroid treatment. The patient showed rapid and significant improvement. ANCAs were later reported positive. ANCA-associated vasculitides present most often as mononeuritis multiplex, but they can mimic GBS and should always be considered in the differential diagnosis, since the treatment strategies for these conditions are radically different.

1. Introduction

Churg-Strauss syndrome, a small-vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCAs), was first described in 1951 by Churg and Strauss as a rare disease characterized by disseminated necrotizing vasculitis occurring among patients with asthma and eosinophilia. It is now termed eosinophilic granulomatosis with polyangiitis (EGPA). The diagnosis of EGPA is based on ACR 1990 criteria (4 or more of the following: asthma, eosinophilia >10%, neuropathy, nonfixed pulmonary infiltrates, paranasal sinus abnormality, and extravascular eosinophils) [1]. During the vasculitic phase, besides renal and pulmonary disease, central and peripheral nervous system involvement may occur, with polynueopathy, radiculopathy, and mononeu-ritis multiplex being common presentations [2]. Guillain-Barre syndrome (GBS) is a clinical syndrome of an acute inflammatory polyneuropathy, characterized by mild sensory loss, ascending weakness, and hypo- or areflexia, progressing to a nadir over up to four weeks. Cerebrospinal fluid evaluation demonstrates albuminocytologic dissociation in 90% of cases. GBS encompasses a number of subtypes with evidence of different clinical, neurophysiological, and immunological mechanisms [3]. In two-thirds there is history of an infection, usually of the upper respiratory system or gastroenteritis. We present a case of EGPA presenting as GBS syndrome. Both GBS and EGPA are rare diseases (approximately 1/100,000), and differentiating between GBS and EGPA-associated vasculitic polyneuropathy is important, considering the different management strategies.

2. Case Presentation

Our patient was a 38-year-old female with an 18-year history of asthma. Two weeks before her admission to the emergency
Table 1: Characteristics of patients with EGP presenting as GBS.

| Reference | Age (sex) | Clinical manifestations | Laboratory findings | NCS | Other | Treatment | Outcome |
|-----------|----------|-------------------------|---------------------|-----|-------|-----------|---------|
| [7]       | 58 M     | Symmetric weakness, hyporeflexia, and asthma | Eosinophilia, elevated ERS, and p-ANCA+ | Mixed demyelinating polyneuropathy and multifocal absent F-waves | Lung infiltrates | P, CyC, and S | Expired |
| [8]       | 57 M     | Symmetric weakness and hyporeflexia | p-ANCA+ and elevated ERS | Demyelinating polyneuropathy and multifocal absent F-waves | | Nephritis | S | Improved |
| [9]       | 51 F     | Symmetric weakness, hyporeflexia, asthma, and nasal polyposis | Eosinophilia, elevated CRP, and ANCA− | Motor asymmetric axonal polyneuropathy and multifocal absent F-waves | | | IvIG and S | Improved |
| [10]      | 74 M     | Symmetric weakness, hyporeflexia, and asthma | Eosinophilia | Mixed demyelinating polyneuropathy | | S and CyC | Improved |
| [11]      | 64 F     | Asymmetric weakness, hyporeflexia, asthma, diplopia, and sinusitis | Elevated ESR, eosinophilia, and p-ANCA+ | Motor axonal and demyelinating polyneuropathy and multifocal absent F-waves | | Multiorgan disease | IvIG, CyC, and S | Expired |

Present case 36 F | Symmetric weakness, hyporeflexia, asthma, purpura, and pansinusitis | Elevated ESR, eosinophilia, and p-ANCA+ | Mixed axonal asymmetric polyneuropathy | | | S and CyC | Improved |

NCS: nerve conduction studies; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IvIG: intravenous immunoglobulin; CyC: cyclophosphamide; P: plasmapheresis; S: steroids.

department, she developed distal bilateral lower limb pares-
thesias that rapidly progressed to weakness that prevented her
from standing from a chair or walking. On examination the
patient was alert and cooperative. She had lower limb weak-
ness (2/5 in both distal and proximal segments, bilaterally),
hyporeflexia, and hypoesthesia. She had distal upper limb
paresthesias, but strength and reflexes were normal. She had
purpuric lesions in the anterior portion of both lower limbs.
Oxygen saturation was normal and she did not complain of
dyspnea. She had no meningeal signs or fever. Her chest X-
ray was normal and the only relevant findings on her routine
blood work-up were a marked eosinophilia (13,200, 53%, normal
range 0–7%) and an elevated erythrocyte sedimentation
rate (49 mm/h; normal range 0–20). Renal function and
urine tests were normal. A head MRI showed pansinusitis.
Cerebrospinal fluid analysis showed 10 leucocytes and normal
glucose and protein. Nerve conduction studies revealed bilat-
eral peroneal, tibial, and sural conduction blocks, with absent
F-waves, as well as a left median nerve conduction block.
The rest of upper extremity nerves were unaffected. Consid-
ering the history of asthma and eosinophilia, we suspected
an eosinophilic vasculitic polyneuropathy and immediately
started our patient on steroids (1g methylprednisolone IV).
The next day there was a dramatic improvement in the
patient’s strength (4/5 in both lower limbs) and c-ANCAs
were reported positive (1: 80, normal range <1: 20). We con-
tinued steroid treatment (5 days), added cyclophosphamide
(1g single dose), and cancelled the planned plasmapheresis.
Bronchial hyperreactivity was confirmed with pulmonary
function tests and a skin biopsy revealed eosinophilic infil-
trates. We diagnosed our patient with EGPA-associated
polyneuropathy. The patient responded well to treatment,
regaining full lower limb strength. She was discharged 10 days
later, without any other organ involvement or new symptoms
at 3 months of follow-up.

3. Discussion

Peripheral neuropathy is quite common in patients with
EGPA. Pathological findings of vasculitic neuropathy are
characterized by axonal degeneration of nerve fibers caused
by vasculitis-induced ischemia. In the largest published series
of patients with EGPA, 51.4–60% had peripheral neuropathy
at presentation [4, 5]. Mononeuritis multiplex was slightly
more common than symmetric polyneuropathy, and the
lower limbs were predominately affected. In contrast to lung
or renal involvement, peripheral neuropathy alone is rarely
life threatening but does significantly affect quality of life.
Although less than 40% of patients with EGPA have positive
ANCAs, this subgroup of patients presents most often with
neuropathy [2, 4]. Our patient was positive for c-ANCA,
while the majority (around 80%) of patients are p-ANCA
positive, although no differences in clinical characteristics
have been found among these subgroups of patients [2, 4].
ANCA positivity has also been associated with lower mortal-
ity [2, 4].

There are at least 6 previous cases reported in the
literature where EGPA presented as GBS (Table 1). In 1996,
Ishiura et al. reported the case of a 74-year-old man who presented with eosinophilic pneumonia and later developed GBS [6]. However, this patient did not meet criteria for EGPA. Ng et al. first reported a case of both clinically and electrophysiologically mimicked GBS, but it was later found to be a case of EGPA due to findings of persistent eosinophilia, positive ANCs, and eosinophilic vasculitis in a sural nerve biopsy [7]. In 1998, Keven et al. reported the case of a patient diagnosed with GBS who later developed ANCA-positive nephrotic syndrome, suggesting that the polyneuropathy could be secondary to necrotizing vasculitis [8]. Since then, at least 3 other cases of EGPA presenting as GBS have been reported, all with acute ascending polyneuropathy and neurophysiologic studies suggestive of GBS [9–11]. Eosinophilia [10] and ANCA positivity [9, 11] were the factors that led to the correct diagnosis, supported in some cases by treatment failure with IV immunoglobulin [10, 11]. All of these cases followed an aggressive course, with multiorgan involvement and death in 1 case [11], and response only after combination immunosuppressive treatment (corticosteroids and cyclophosphamide) in the other 2 [9, 10].

Although our patient also presented with a symmetric ascending paralysis and hyporeflexia, a history of asthma, severe eosinophilia, and skin purpuric lesions raised our suspicion of EGPA. Compared to the cases mentioned above, our patient was younger, received early treatment with steroids, and had no other organ involvement, and her course was relatively benign. EGPA and other vasculitides should always be part of the differential diagnosis of GBS, as the first line treatments may differ. While steroids are of no use (and may even be harmful) in GBS, they are the mainstay of treatment in EGPA [2]. Adding cyclophosphamide could reduce recurrence of EGPA and may be life-saving when there is multiple organ involvement. On the other hand, IV immunoglobulin and plasmapheresis may be effective in both EGPA and GBS [3].

Consent

The patient described in the case report has given their informed consent for the case report to be published.

Conflict of Interests

The authors report no conflict of interests.

References

[1] A. T. Masi, G. G. Hunder, J. T. Lie et al., “The American college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis),” *Arthritis & Rheumatism*, vol. 33, no. 8, pp. 1094–1100, 1990.
[2] A. Greco, M. I. Rizzo, A. de Virgilio et al., “Churg–Strauss syndrome,” *Autoimmunity Reviews*, vol. 14, no. 4, pp. 341–348, 2015.
[3] J. B. Winer, “An update in guillain-barré syndrome,” *Autoimmune Diseases*, vol. 2014, Article ID 793024, 6 pages, 2014.
[4] C. Comarmond, C. Pagnoux, M. Khellaf et al., “Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort,” *Arthritis & Rheumatism*, vol. 65, no. 1, pp. 270–281, 2013.
[5] J. Wolf, V. Schmitt, F. Palm, A. J. Grau, and R. Bergner, “Peripheral neuropathy as initial manifestation of primary systemic vasculitides,” *Journal of Neurology*, vol. 260, no. 4, pp. 1061–1070, 2013.
[6] Y. Ishiura, H. Tsuji, S. Takeda et al., “Acute eosinophilic pneumonia accompanied by Guillain-Barré syndrome,” *British Journal of Clinical Practice*, vol. 50, no. 5, pp. 283–285, 1996.
[7] K. K. P. Ng, H. M. Yeung, K. T. Loo, H. M. Chan, C. K. Wong, and P. C. K. Li, “Acute fulminant neuropathy in a patient with Churg-Strauss syndrome,” *Postgraduate Medical Journal*, vol. 73, no. 858, pp. 236–238, 1997.
[8] K. Keven, G. Nergisoglu, S. Erturk et al., “A case of Guillain-Barré syndrome complicated by nephrotic syndrome and p-ANCA positivity,” *Nephron*, vol. 80, no. 3, pp. 361–362, 1998.
[9] N. Riva, F. Cerri, C. Butera et al., “Churg Strauss syndrome presenting as acute neuropathy resembling Guillain Barré syndrome: case report,” *Journal of Neurology*, vol. 255, no. 11, pp. 1843–1844, 2008.
[10] M. Djukic, H. Schmidt, C. Mazurek, F. König, S. Schweyer, and R. Nau, “A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome,” *Nervenarzt*, vol. 79, no. 4, pp. 457–461, 2008.
[11] L. De Toni Franceschini, S. Amadio, M. Scarlato et al., “A fatal case of Churg-Strauss syndrome presenting with acute polyneuropathy mimicking Guillain-Barré syndrome,” *Neurological Sciences*, vol. 32, no. 5, pp. 937–940, 2011.